ArticleBMC medicine2025
Association between levothyroxine supplementation for hypothyroidism in late pregnancy and risk of prematurity: a population-based cohort study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypothyroidism in pregnancy is associated with obstetrical and fetal complications, such as prematurity. However, whether its management by levothyroxine affects the risk of prematurity is not yet clear.
methodsWe conducted a cohort study within the Quebec Pregnancy Cohort including pregnancies with hypothyroidism from January 1, 1998, through December 31, 2015. In primary analyses, we considered levothyroxine exposure (yes/no), total duration, mean daily dose, and cumulative dose in the 2-months period before delivery (for preterm deliveries) or before 37th weeks' gestation (for term deliveries). Secondly, levothyroxine dosage before and after the beginning of the second trimester were compared, and pregnancies were categorized in increased or constant dosage groups. Lastly, levothyroxine was also defined as a time-varying daily exposure from the 14th weeks' gestation until delivery or 37th weeks' gestation, whichever came first. Prematurity was defined as giving birth before the 37th weeks' gestation. Term pregnancies were censored at 37th weeks' gestation because they were no longer at risk of prematurity afterwards. Generalized estimating equations and Cox-proportional hazard models, adjusted for potential confounders, were used to calculate adjusted relative risks (aRRs) and hazard ratios (aHRs), respectively.
resultsA total of 9489 pregnant individuals with hypothyroidism were included. Among them, 6667 (70.3%) were exposed to levothyroxine in the 2-months time-window. Adjusting for potential confounders, no association was observed between levothyroxine exposure (aRR, 0.98; 95% CI, 0.81-1.20) and the risk of prematurity compared to non-exposed. Also, no association between levothyroxine duration (> 30 days: aRR, 0.99; 95% CI, 0.81-1.21), cumulative dose (> 7125 mcg: aRR, 0.97; 95% CI, 0.73-1.27) or mean daily dose (> 125 mcg/day: aRR, 0.95; 95% CI, 0.72-1.26) and the risk of prematurity was observed, compared to non-exposure. Finally, the risk of prematurity did not vary between increased or constant dosage groups (aRR, 0.84; 95% CI, 0.67-1.05). Similarly, time-varying exposure analysis did not show any association between levothyroxine exposure and prematurity risk (aHR, 0.95; 95% CI, 0.81-1.11).
conclusionsLevothyroxine supplementation in late pregnancy among individuals with hypothyroidism was not associated with prematurity risk. Our findings support the safe use of levothyroxine during gestation and might be useful for the current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.